The phase III SIRFLOX trial showed that selective internal radiation therapy delivered to liver metastases in patients with colorectal cancer, plus chemotherapy, improved local control, although median progression-free survival for the whole population was not affected.

Median progression-free survival of liver metastases was approximately 10 months overall in the study of 530 patients.

In patients with liver-only or liver-predominant metastases, however, median progression-free survival was improved by almost 8 months with the addition of selective internal radiation therapy.

Toxicity was slightly increased with the additional treatment modality. ■